Zenith may be waiting to time its announcement of the ZEN-3694/enzalutamide mCRPC trial results with going public. Also, with Resverlogix's BETonMACE set to read out soon, and with ZCC holding the Resverlogix royalty preferred shares, it makes sense to wait for BETonMACE announcement before Zenith goes public. The valuations of ZCC and ZEL could change tremendously with these two catalysts. And this all assumes that a buyout of ZCC and/or ZEL doesn't happen first before they get the chance to go public.

BearDownAZ